*3.3. Patients Outcome in Relation to TP53 Mutations*

No statistically significant associations were found between *TP53* mutations and ORR and DCR (Table S3). When considering any type of *TP53* mutation with regard to PFS, no association was found; however, significant results were observed considering only *TP53* exon 8 mutations. As previously reported [6], patients with this gene mutation showed a shorter median PFS than non-exon 8 mutated and wild type *TP53* patients: 5.8 months (95% CI: 2.4–10.2) vs. 14.4 (95% CI: 6.7–21.8) and 12.4 (95% CI: 10.0–15.0), respectively (Figure 1A). These patients also showed a poorer OS as compared with the other groups, even though this result was not statistically significant: median OS were 18.53 months (95% CI: 7.3–NR), 34.8 (95% CI: 21.6–NR), 27.3 (95% CI: 20.2–52.9), respectively (Figure 1B).

The presence of *TP53* exon 8 mutation seemed to be associated with a worse prognosis in a similar way in the patients with the different *EGFR* mutations, both in terms of PFS and OS.

In particular, patients with wild type *TP53* exon 8 had a better clinical outcome independently by *EGFR* status: median PFS and OS were 12.9 (95% CI: 10.0–16.3) and 29.7 months (95% CI: 23.0–60.5) for patients with *EGFR* exon 19 deletion vs. 12.4 months (95% CI: 7.9–15.0) and 23.2 months (95% CI: 19.2–63.7) for those with other *EGFR* mutations, respectively; in the subgroup of patients with *TP53* exon 8 mutations, median PFS and OS were 5.8 months (95% CI: 2.5–NR) and 21.9 months (95% CI: 7.3–NR) for patients with *EGFR* exon 19 deletion vs. 6.4 (95% CI: 2.4–NR) and 18.5 months (95% CI: 7.6–NR) for those with other *EGFR* mutations. In Table S4, the univariate Cox analysis results are reported.

**Figure 1.** Progression-free survival (**A**) and Overall Survival (**B**) of patients according to *TP53.*
